Compare Sana Biotechnology Inc (SANA) vs T Rowe Price Group Inc (TROW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs T Rowe Price Group Inc — how do they compare? Sana Biotechnology Inc trades at $2.79 (market cap $836.71M), while T Rowe Price Group Inc trades at $105.16 (market cap $22.23B). The key difference: T Rowe Price Group Inc is far larger — about 26.6× Sana Biotechnology Inc's market cap, and T Rowe Price Group Inc pays a 4.99% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sana Biotechnology Inc for 23 Days and T Rowe Price Group Inc for 115 Days on average.
| SANA | TROW | |
|---|---|---|
Market Cap | $836.71M | $22.23B |
Volume | 4,507,444 | 2,834,949 |
Sector | Health | Financials |
52-Week High | $5.92 | $121.68 |
52-Week Low | $2.68 | $86.19 |
Typical Hold Time | 23 Days | 115 Days |
Enterprise Value | $749.96M | $19.43B |
Dividend Yield | — | 4.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent news highlights multiple investor conference presentations and ongoing legal scrutiny regarding fiduciary duties.
Despite strong analyst support (82% buy ratings), SANA's lack of revenue generation and negative profitability metrics present substantial investment risk. The company's cash flow remains negative, requiring continued financing. Near-term catalysts include upcoming Q3 earnings and clinical developments, but investors should weigh the high-risk profile against potential long-term biotechnology breakthroughs.
T. Rowe Price Group (TROW) trades at $104.23, up 0.15% on the day, with a bearish technical signal but solid fundamentals. The stock shows consistent revenue growth, reaching $7.31B in 2025, and a strong net income margin of 29.26%. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains a 40-year dividend growth streak, paying $1.30 per share in H2 2026. Analyst consensus is mixed, with a $110.50 price target, but technical indicators point to near-term resistance at $105.
Outlook: TROW offers value with a low P/E of 10.46 and robust profitability, but faces headwinds from net outflows and bearish technicals. Investment opportunity lies in its dividend aristocrat status and earnings momentum, while risks include fee pressure from market volatility and competitive threats. The stock is a hold for income investors, with upside potential if operational trends improve.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →
